The standard treatment of operable breast adenocarcinomas too large to be amenable to breast-conserving surgery is mastectomy with axillary lymph node clearance. Several randomised studies have compared neoadjuvant with adjuvant chemotherapy. In these studies, the locoregional treatment could be either surgery or radiotherapy or a combination of both. There was no significant difference in terms of locoregional control and overall (OS) or disease-free survivals ([Mauri *et al*, 2005](#bib25){ref-type="other"}). The principal clinical benefit of a neoadjuvant medical treatment was, in the case of good clinical response, avoiding mastectomy. However, data regarding the specific behaviour of invasive lobular carcinomas (ILC), a histological subtype of breast cancers representing 5--15% of all breast cancer cases, are still scarce in this therapeutic setting. Lobular carcinomas are characterised by a specific morphology with discohesive small cells usually associated with estradiol receptor (ER), progesterone receptor (PR) positivity and with a low proliferation rate ([Sastre-Garau *et al*, 1996](#bib34){ref-type="other"}). These factors are now well-established predictive markers of poor response to neoadjuvant chemotherapy ([Pierga *et al*, 2003](#bib27){ref-type="other"}). We, and others, have previously shown that ILC are often diagnosed as larger tumours than invasive ductal carcinomas (IDC) ([Sastre-Garau *et al*, 1996](#bib34){ref-type="other"}), and for which a neoadjuvant treatment could be chosen to increase the rate of conservative surgery. This study aims to compare the outcome of lobular *vs* ductal carcinomas under neoadjuvant chemotherapy and to report their locoregional control.

MATERIALS AND METHODS
=====================

Between January 1989 and December 1999, a total of 803 patients, with operable, clinical stage II/IIIA, either ductal or lobular invasive breast carcinoma, not amenable to initial breast-conserving surgery, were treated at the Institut Curie with primary chemotherapy. Out of them, 750 had an initial core-needle biopsy before the start of treatment and will be studied here -- 78 patients with lobular invasive carcinoma and 672 with ductal invasive carcinomas. The other 53 had initial fine-needle aspiration and underwent biopsy after the start of the chemotherapy. Median follow-up was 117 months (10--188). Histological classification was made according to the WHO criteria. Histological grading was performed according to the Scarff Bloom and Richardson method ([Bloom and Richardson, 1957](#bib2){ref-type="other"}). Positivity to ER and PR was determined by biochemistry. Hormonal receptors (HR) were considered positive when either ER or PR was positive. All slides of lobular carcinomas were retrospectively reviewed. The E-cadherin expression was assessed by immunohistochemistry.

Treatment decisions were not adapted to the histological type. The following information regarding the treatment details apply both to lobular and ductal carcinomas. No patient received neoadjuvant hormonal therapy. All patients received a median of four (range: 1--6) cycles of neoadjuvant chemotherapy. Chemotherapy between 1989 and 1995, consisted of FAC with 5-Fluorouracil (F) on days 1, 3, 5 and 8, adriamycin (A) on days 1 and 8, and cyclophosphamide (C) on days 1 and 8 ([Pierga *et al*, 2003](#bib27){ref-type="other"}). It was subsequently simplified according to a more classical regimen with adriamycin or epirubicin (E), cyclophosphamide and/or fluorouracil every 21 days for six cycles (FAC, FEC, AC or EC) ([French Adjuvant Study Group, 2001](#bib18){ref-type="other"}).

Response to primary chemotherapy was assessed clinically as reported by [Pierga *et al* (2003)](#bib27){ref-type="other"}, according to the International Union against Cancer Criteria. Complete response was defined as the total resolution of the breast mass and regional lymph adenopathy as determined by physical examination; partial response was defined as 50% or greater reduction in the product of the two largest perpendicular dimensions of the breast mass and regional adenopathy; minor response was defined as less than a 50% reduction in the product of the two largest perpendicular dimensions. Stable disease was defined as no measurable change in the product of the two largest perpendicular dimensions, and progressive disease was defined as an increase of at least 25% in the product of the two largest perpendicular dimensions. Clinical response was dichotomised in two groups: \<50 and ⩾50%.

Local treatments consisted in breast surgery and/or radiotherapy. Whenever feasible, it consisted in tumorectomy followed by radiotherapy. When the tumour did not become amenable to conservative surgery, the decision was usually made to perform a mastectomy, followed in most cases by radiotherapy. However, some patients, because of a desire to conserve their breasts, received radiotherapy as first (followed by either tumorectomy or mastectomy) or exclusive local treatment. In other instances, this sequence of preoperative or exclusive radiotherapy was chosen for tumours with very good response to chemotherapy. Radiotherapy delivered a mean dose of 51.4 Gy (s.d. 2.5 Gy) in 2 Gy fractions to the breast, using either standard or lateral decubitus techniques ([Campana *et al*, 2005](#bib8){ref-type="other"}), or to the chest wall. A mean dose of 45 Gy (s.d., 2 Gy) in 23--25 fractions was usually delivered to the internal mammary chain and the supraclavicular area with the addition of an axillary irradiation when there was an important axillary involvement or in the absence of an axillary lymph node dissection. In the case of breast--conserving treatments, a boost was delivered to the tumour or to the tumorectomy bed by either external beam radiotherapy or brachytherapy. The mean total dose was 64 Gy (s.d., 7.6 Gy) to the tumorectomy bed for postoperative radiotherapy and 73 Gy (s.d., 7.6 Gy) to the tumour in the case of exclusive radiotherapy. Patients were followed up clinically every 6 months for the first 5 years and annually thereafter. Mammograms and/or ultrasound scans were performed annually.

Statistics
----------

All studied factors are reported in the relevant Tables.

Differences between groups were analysed by χ^2^ tests for categorical variables and Student\'s *t*-test for continuous variables.

Univariate logistic regressions were performed to identify predictive factors of clinical response (⩾50%) and to estimate crude odds ratios (OR). Multivariate logistic regression analyses permitted to estimate the OR of variables independently associated with clinical response.

Survival data were defined as the time from diagnosis of breast cancer until the occurrence of event, that is, locoregional recurrence (LRR) defined as any recurrence occurring in the treated breast or in the ipsilateral chest wall or regional lymph node-bearing areas (internal mammary chain, axilla and supraclavicular area) and death (OS). Recurrence-free and alive patients were censored at the date of their last known contact. The OS and LRR rates were calculated by the Kaplan--Meier method, and groups were compared using a log-rank test. Multivariate analysis was carried out to assess the relative influence of prognostic factors on locoregional control, using the Cox stepwise procedure after stratification on the local treatment (exclusive/preoperative radiotherapy *vs* postoperative radiotherapy) ([Cox and Oakes, 1984](#bib14){ref-type="other"}). Missing values (tumour grade, receptor levels and mitotic index) were coded as separate categories of the variable and retained in the model.

Significance level was 0.05. Analyses were performed using Splus 2000 software (Mathsoft Inc., Seattle, WA, USA).

RESULTS
=======

Patients\' and tumours\' characteristics according to the histological type of invasive carcinoma
-------------------------------------------------------------------------------------------------

The comparison of the 78 patients with lobular invasive carcinoma with the 672 with ductal invasive carcinomas is summarised in [Table 1](#tbl1){ref-type="table"}.

Patients diagnosed with lobular invasive carcinomas were significantly older than patients with ductal carcinomas. Lobular cancers were significantly larger (median size of 50 *vs* 40 mm; *P*\<10^−3^) with more HRs positive (HR+; 87 *vs* 73%; *P*=0.02) and lower histological grades than ductal carcinomas (grade 1; 41 *vs* 12%; *P*\<10^−3^).

Response to primary chemotherapy and local treatment according to histological type
-----------------------------------------------------------------------------------

Clinical response to primary chemotherapy was significantly better for ductal invasive carcinomas than for lobular (⩾50% of clinical response in 60% for ductal *vs* 47% for lobular; *P*=0.04; [Table 2](#tbl2){ref-type="table"}). The rates of breast-conserving treatments for lobular carcinomas was lower than that for ductal carcinomas, but the difference was not statistically significant (54% (42 out of 78) *vs* 65% (434 out of 672); *P*=0.07) and more patients with lobular carcinomas received local treatment with either exclusive radiotherapy or preoperative radiotherapy compared with ductal carcinomas (40 (31 out of 78) *vs* 26% (178 out of 672); *P*=0.02). If we look at patients who had surgery, excluding patients with radiotherapy alone as local treatment, there were significantly fewer breast conservations for lobular than for ductal invasive carcinomas: 24 out of 78 (31%) *vs* 333 out of 672 (50%), *P*=0.001. Rates of pathological complete response (for all patients who had undergone surgery) were respectively 9% (40 out of 457, 118 unknown) for ductal and 8% (4 out of 50, 10 unknown) for lobular (*P*=0.94).

Other factors of good clinical response found in univariate analysis ([Table 3](#tbl3){ref-type="table"}) were clinical T2 *vs* T3, HR+ *vs* HR− and high histological grade *vs* low and intermediate. In multivariate analysis, only high grade was significantly associated with a higher rate of clinical response.

Comparison of patients who underwent breast conservation with either preoperative/exclusive radiotherapy or postoperative radiotherapy
--------------------------------------------------------------------------------------------------------------------------------------

Among patients who received breast-conserving treatments, those with preoperative/exclusive radiotherapy had tumours that were significantly more often clinically T3 (23 *vs* 15%; *P*=0.03), lobular (15 *vs* 5%; *P*\<10^−3^) and responded clinically less to primary chemotherapy (clinical response ⩾50% respectively 63 *vs* 78%; *P*\<10^−3^) than those with postoperative radiotherapy ([Table 4](#tbl4){ref-type="table"}).

Survivals
---------

Overall survival rates at, respectively, 5 and 10 years were 81 (95% CI, 78--84%) and 66% (95% CI, 62--70%).

Locoregional control rates at, respectively, 5 and 10 years were 83 (95% CI, 81--86%) and 75% (95% CI, 71--78%) but, when considering only patients treated with breast conservation, 81 (95% CI, 77--85%) and 71% (95% CI, 67--76%).

Prognostic factors
------------------

### For locoregional control

In univariate analysis, factors that were found to be associated with a higher locoregional recurrence rate were young age, cN1, HR− and having undergone a breast-conserving treatment ([Table 5](#tbl5){ref-type="table"}). The histological subtype classification (lobular *vs* ductal) was not found to be prognostic for locoregional control, with values at 10 years being 73 and 75%, respectively (RR=1 (0.6--1.7); *P*=0.9).

On forward stepwise multivariate analysis (Cox model) stratified on local treatment, only the young age (\<40 years) remained statistically significant.

When considering only patients treated with breast conservation ([Table 6](#tbl6){ref-type="table"}), the only factors found in univariate analysis to be associated with a higher locoregional recurrence rate were young age and treatment with preoperative or exclusive radiotherapy. The histological subtype classification (lobular *vs* ductal) was not found to be prognostic for locoregional control with, respectively, at 10 years, a locoregional control of 62 and 72% (RR=1.5 (0.9--2.6); *P*=0.12).

On multivariate analysis (Cox model) stratified on local treatment, only young age (\<40 years) remained statistically associated with worse locoregional control.

### For overall survival

In univariate analysis, factors that were found to be associated with a lower overall survival rate were cT3, cN1, HR−, histological grade 2 and 3 and mitotic index grade 2 and 3 ([Table 7](#tbl7){ref-type="table"}). The histological subtype classification (lobular *vs* ductal) was not found to be prognostic for overall survival with, respectively, at 10 years, a rate of 72% (95% CI, 62--84%) and 65% (95% CI, 61--69); RR=0.84 (0.55--1.30); *P*=0.44.

On forward stepwise multivariate analysis (Cox model) stratified on local treatment, cT3, cN1, HR−, histological grade 2/3 and absence of clinical response were statistically significant.

DISCUSSION
==========

This retrospective study spans a period of 10 years with patients treated between 1989 and 1999. The follow-up is long with a median at 10 years and makes the study of locoregional survival relevant. The tumour characteristics of lobular carcinomas were those already found by Sastre and co-workers and others ([Sastre-Garau *et al*, 1996](#bib34){ref-type="other"}; [Cristofanilli *et al*, 2005](#bib15){ref-type="other"}). Patients diagnosed with lobular invasive carcinomas were significantly older ([Sastre-Garau *et al*, 1996](#bib34){ref-type="other"}) than patients with ductal tumours. Lobular cancers were significantly larger ([Sastre-Garau *et al*, 1996](#bib34){ref-type="other"}; [Cristofanilli *et al*, 2005](#bib15){ref-type="other"}; [Tubiana-Hulin *et al*, 2006](#bib40){ref-type="other"}) with more HRs ([Sastre-Garau *et al*, 1996](#bib34){ref-type="other"}; [Mathieu *et al*, 2004](#bib24){ref-type="other"}; [Cristofanilli *et al*, 2005](#bib15){ref-type="other"}; [Tubiana-Hulin *et al*, 2006](#bib40){ref-type="other"}) and lower histological ([Sastre-Garau *et al*, 1996](#bib34){ref-type="other"}; [Tubiana-Hulin *et al*, 2006](#bib40){ref-type="other"}) or nuclear ([Cristofanilli *et al*, 2005](#bib15){ref-type="other"}; [Tubiana-Hulin *et al*, 2006](#bib40){ref-type="other"}) grade than ductal carcinomas.

Because of the frequent use of either exclusive or preoperative radiotherapy, the study of pathological response in our series was not relevant. Bearing in mind the mandatory caution in interpreting clinical response ([Bollet *et al*, 2007](#bib5){ref-type="other"}), we found that the response to primary chemotherapy was significantly better for ductal invasive carcinomas than for lobular (⩾50% of clinical response in 60% for ductal *vs* 47% for lobular; *P*=0.04), confirming the notion developed by others that lobular carcinomas responded less than ductal carcinomas to neoadjuvant chemotherapy ([Mathieu *et al*, 2004](#bib24){ref-type="other"}; [Cristofanilli *et al*, 2005](#bib15){ref-type="other"}; [Tubiana-Hulin *et al*, 2006](#bib40){ref-type="other"}; [Wenzel *et al*, 2006](#bib45){ref-type="other"}; [Katz *et al*, 2007](#bib21){ref-type="other"}). However, in the present study, in multivariate analysis, only high grade was significantly associated with a higher rate of clinical response. This result is therefore in agreement with the Nomograms\'s design proposed online, which does not take into account the histological type of the tumour when deciding on the therapeutic option ([Rouzier *et al*, 2005b](#bib32){ref-type="other"}). There is room to better define biological predictive factors of response to neoadjuvant chemotherapy to screen patients who would benefit most from this therapeutic option ([Sotiriou *et al*, 2002](#bib38){ref-type="other"}; [Chang *et al*, 2005](#bib10){ref-type="other"}; [Gianni *et al*, 2005](#bib19){ref-type="other"}; [Rouzier *et al*, 2005a](#bib31){ref-type="other"}; [Pierga *et al*, 2007](#bib28){ref-type="other"}). Lobular carcinomas had reduced clinical responses to neoadjuvant chemotherapy, while responses to breast-conserving treatments were fewer, although not significantly (54% (42 out of 78) *vs* 65% (434 out of 672); *P*=0.07). The lower rate of breast conservation in lobular *vs* ductal invasive carcinoma could also be due to the larger size of ILC. The most striking data are the high rate of breast conservation for both ductal and even more so for lobular carcinomas when compared to the rates in the literature that range, respectively, between 30--48 and 16--31% ([Mathieu *et al*, 2004](#bib24){ref-type="other"}; [Cristofanilli *et al*, 2005](#bib15){ref-type="other"}; [Tubiana-Hulin *et al*, 2006](#bib40){ref-type="other"}). This is explained in our series by the use of either exclusive or preoperative radiotherapy, particularly for large tumours with a poor response to neoadjuvant chemotherapy and, therefore, more frequently for lobular (40%) than for ductal (26%) carcinomas. Because of the retrospective nature of this study, we could not report the reason for the choice of performing preoperative or exclusive radiotherapy. However, as one can see from [Table 2](#tbl2){ref-type="table"}, the proportion of patients who received radiotherapy immediately after primary chemotherapy and who actually went on to have successful breast-conserving treatments was 80 and 84%, respectively, for IDC and ILC.

Despite being associated with large tumour size and less clinical response to primary chemotherapy, lobular subtype was not found associated with either worse locoregional control, even in the subgroup of only patients who had been treated with breast conservation, or worse overall survival. It should, however, be noted that in this series, patients treated with exclusive or preoperative radiotherapy fared worse in terms of locoregional control than others, perhaps also because of a selection of patients with poor prognosis. This opens the debate as to whether radiotherapy could not play a role in increasing the rate of breast-conserving treatments for some invasive carcinomas, as it is an important part of the treatment of large breast cancers ([Whelan *et al*, 2000](#bib46){ref-type="other"}; [Clarke *et al*, 2005](#bib11){ref-type="other"}) and has been shown to achieve complete clinical response (6--41%) with doses compatible with planned secondary surgeries ([Calitchi *et al*, 1991](#bib7){ref-type="other"}; [Scholl *et al*, 1994](#bib35){ref-type="other"}; [Broet *et al*, 1999](#bib6){ref-type="other"}; [Bollet *et al*, 2006](#bib4){ref-type="other"}). At the Institut Curie, the S6 trial randomised premenopausal women between chemotherapy and radiotherapy as an initial treatment for large breast cancers ([Scholl *et al*, 1994](#bib35){ref-type="other"}). There was no difference in the 10-year OS ([Broet *et al*, 1999](#bib6){ref-type="other"}). Out of 69 tumours still palpable after four cycles of FAC (5-fluorouracil, adriamycine and cyclophosphamide), 42 (61%) achieved complete clinical response after 54 Gy. In contrast with chemotherapy ([Vincent-Salomon *et al*, 2004](#bib42){ref-type="other"}; [Andre *et al*, 2005](#bib1){ref-type="other"}), which is more effective in proliferative tumours, the effect of radiotherapy does not seem to depend on the degree of proliferation (or on the histological grade) ([Remvikos *et al*, 1993](#bib29){ref-type="other"}; [Rozan *et al*, 1998](#bib33){ref-type="other"}; [Clarke *et al*, 2006](#bib12){ref-type="other"}). Radiotherapy could thus theoretically play a role in increasing the rate of breast conservation for tumours that fail to sufficiently shrink with primary chemotherapy because of low proliferation, as in the case of lobular carcinomas. Another study performed at the Institut Curie showed a similar rate of pathological complete response with preoperative concurrent chemoradiotherapy for lobular and for ductal invasive carcinomas (31 *vs* 22%; *P*=0.5; [Bollet *et al*, 2006](#bib4){ref-type="other"}). [Ring *et al* (2003)](#bib30){ref-type="other"} found, in a retrospective study comparing surgery (either breast-conserving or mastectomy) and exclusive radiotherapy for women who achieved clinical complete responses after primary chemotherapy, a nonsignificant trend toward increased locoregional-only recurrence for the no surgery group. However, they also found that patients achieving both clinical and ultrasound complete responses, and not undergoing surgery, had a low (8%) rate of locoregional recurrence at 5 years. Additionally, MRI has also proven to be useful in the assessment of the tumour response to chemotherapy ([Thibault *et al*, 2004](#bib39){ref-type="other"}; [Warren *et al*, 2004](#bib44){ref-type="other"}; [Partridge *et al*, 2005](#bib26){ref-type="other"}; [Segara *et al*, 2007](#bib36){ref-type="other"}). This good value of MRI in the evaluation of tumour response should also apply to ILC as, even though ILC is still a challenge for MRI ([Kinkel and Hylton, 2001](#bib22){ref-type="other"}), the addition of MRI to mammography still increases the sensitivity in the detection of ILC ([Gilles *et al*, 1994](#bib20){ref-type="other"}; [Sittek *et al*, 1998](#bib37){ref-type="other"}) and, most importantly in the case of the response evaluation, the volumetric assessment is improved ([Boetes *et al*, 2004](#bib3){ref-type="other"}; [Fabre Demard *et al*, 2005](#bib17){ref-type="other"}; [Caramella *et al*, 2007](#bib9){ref-type="other"}; [Mann *et al*, 2008](#bib23){ref-type="other"}). This raises the question of whether patients who achieve complete clinical and imaging response could in some cases entirely avoid surgery. This issue, needless to say, would need to be properly assessed in a prospective randomised trial. Additionally, to really benefit from higher rates of breast conservation, one needs to closely evaluate the cosmetic effects of this therapeutic approach but which could not be assessed in our study. One particular concern is indeed that it is associated with worse cosmetic results, because they deteriorate with the radiotherapy total dose (whole breast+boost; [Vrieling *et al*, 1999](#bib43){ref-type="other"}), with chemotherapy ([Vass and Bairati, 2005](#bib41){ref-type="other"}), and when radiotherapy is given pre- rather than post-operatively, both in the case of standard ([Durand *et al*, 1987](#bib16){ref-type="other"}) or oncoplastic ([Clough *et al*, 2003](#bib13){ref-type="other"}) surgeries.

In conclusion, our series confirmed that lobular carcinomas demonstrate a lower response rate to neoadjuvant chemotherapy than ductal carcinomas, but that in multivariate analysis only low histological grades remained predictive of poor response to chemotherapy. The breast conservation in our series was higher than the one expected from the literature for both histological types. The most obvious explanation was the frequent use of either preoperative or exclusive radiotherapy after chemotherapy, especially for tumours with a poor response to chemotherapy and therefore for lobular carcinomas. The lobular type had no adverse effect on locoregional control even in the group of patients treated with breast conservation. Further studies are still needed to evaluate the exact role of preoperative/exclusive radiotherapy after neoadjuvant chemotherapy, not only in terms of efficacy but also of tolerance and long-term cosmetic effects.

We thank all the members of the Breast Cancer Study Group at the Institut Curie who have contributed to the completion of this study. We also thank Chantal Gautier for her help in the management of the patients\' data.

###### 

Tumour and treatment characteristics according to the histological type of the invasive breast carcinoma

                                                 **Ductal (*N*=672)**   **Lobular (*N*=78)**            
  --------------------------------------------- ---------------------- ---------------------- ---- ---- ---
  *Age (DM*=*0*)                                       \<10^−2^                                         
   Median (min--max) in years                        46 (24--70)            49 (39--68)                 
                                                                                                          
  *Menopause (DM*=*0*)                                   0.88                                           
   Yes                                                   167                     25            20   26    
   No                                                    505                     75            58   74    
                                                                                                          
  *Clinical T stage (DM*=*0*)                            0.03                                           
   T2                                                    506                     75            50   64    
   T3                                                    166                     25            28   36    
                                                                                                          
  *Clinical N stage (DM*=*0*)                            0.16                                           
   N0                                                    411                     61            54   69    
   N1                                                    261                     39            24   31    
                                                                                                          
  *Tumour clinical maximal diameter (DM*=*0*)          \<10^−3^                                         
   Median (min--max) in mm                           40 (20--70)            50 (25--70)                 
                                                                                                          
  *Histological grade (DM*=*4*)^a^                     \<10^−3^                                         
   1                                                      82                     12            32   41    
   2                                                     332                     50            30   38    
   3                                                     210                     31            7    9     
                                                                                                          
  *Mitoses per 10 HPF (DM*=*72*)                       \<10^−3^                                         
   (0--10)                                               129                     21            53   80    
   (11--21)                                              182                     30            7    11    
   ⩾22                                                   291                     48            6    9     
                                                                                                          
  *Hormonal receptors (DM*=*118*)                        0.02                                           
   ER+ and/or PR+                                        412                     73            54   87    
   ER−/PR−                                               158                     28            8    13    

HPF=high-power field; DM=data missing.

Menopause defined, for women with intact uterus, as 2 years of amenorrhea and for the others, biologically.

Percentages were rounded, so, when added, the sum may not be exactly 100.

Fifty-three tumours (44 ductal and 9 lobular) could not be evaluated.

###### 

Clinical responses to neoadjuvant chemotherapy

                                                          **Ductal (*N*=672)**   **Lobular (*N*=78)**            
  ------------------------------------------------------ ---------------------- ---------------------- ---- ---- ---
  *Clinical response to primary chemotherapy (DM*=*7*)            0.04                                           
   ⩾50%                                                           397                     60            37   47    
   \<50%                                                          268                     40            41   53    
                                                                                                                   
  *Local treatment (DM*=*0*)                                      0.01                                           
   Tumorectomy followed by RT                                     292                     43            16   21    
   Mastectomy followed by RT                                      160                     24            25   32    
   Mastectomy alone                                                42                     6             6    8     
   RT followed by tumorectomy                                      45                     7             8    10    
   RT followed by mastectomy                                       36                     5             5    6     
   RT alone                                                        97                     14            18   23    

DM=data missing; RT, radiorherapy.

Local treatments.

Percentages were rounded, so, when added, the sum may not be exactly 100.

###### 

Predictive factors of clinical response (\>50%) according to univariate and multivariate analyses

                                        **Univariate analysis**   **Multivariate analysis**         
  ------------------------- ----- ---- ------------------------- --------------------------- ------ ----------------
  *Age*                                                                                             
   \>40                      548   58                                         1                             
   ⩽40                       138   55             0.6                  0.9 (0.6--1.3)                       
                                                                                                            
  *Menopause*                                                                                       
   No                        512   56                                                                       
   Yes                       174   61             0.3                  1.2 (0.8--1.7)                       
                                                                                                            
  *Clinical tumour stage*                                                                           
   cT2                       515   60                                                                       
   cT3                       171   51          \<0.05^a^               0.7 (0.5--0.99)        0.12   0.7 (0.5--1.1)
                                                                                                            
  *Clinical nodal status*                                                                           
   cN0                       425   56                                                                       
   cN1                       261   60             0.3                  1.2 (0.9--1.6)                       
                                                                                                            
  *Histological type*                                                                               
   Ductal                    617   59                                                                       
   Lobular                   69    43            0.02                  0.5 (0.3--0.9)         0.23   0.7 (0.4--1.3)
                                                                                                            
  *Hormonal receptors*^b^                                                                           
   HR+                       433   55                                                                       
   HR−                       144   65            0.03                  1.5 (1.0--2.3)         0.09   1.4 (0.9--2.1)
                                                                                                            
  *Histological grade*                                                                              
   Grade 1                   113   42                                         1                            1
   Grade 2                   360   59            0.003                 1.9 (1.3--3.0)         0.02   1.8 (1.1--3.0)
   Grade 3                   213   63          \<10^−3^                2.3 (1.4--3.7)         0.02   2.0 (1.1--3.4)

ER=estradiol receptor; HR=hormonal receptor; PR=progesterone receptor.

Factors entered in the multivariate analysis.

HR+ if ER+ and/or PR+.

###### 

Comparison of patients treated with breast conserving treatment with either exclusive/preoperative radiotherapy or postoperative radiotherapy

                                                 **Exclusive or preoperative radiotherapy (*N*=168)^a^**   **Postoperative radiotherapy (*N*=308)**             
  --------------------------------------------- --------------------------------------------------------- ------------------------------------------ ----- ---- ---
  *Menopause (DM*=*0*)                                                    0.44                                                                                  
   No                                                                      121                                                72                      232   75    
   Yes                                                                     47                                                 28                      76    25    
                                                                                                                                                                  
  *Clinical T stage (DM*=*0*)                                             0.03                                                                                  
   T2                                                                      129                                                77                      262   85    
   T3                                                                      39                                                 23                      46    15    
                                                                                                                                                                  
  *Clinical N stage (DM*=*0*)                                             0.21                                                                                  
   N0                                                                      105                                                63                      210   68    
   N1                                                                      63                                                 37                      98    32    
                                                                                                                                                                  
  *Histological type (DM*=*0*)                                          \<10^−3^                                                                                
   Ductal                                                                  142                                                85                      292   95    
   Lobular                                                                 26                                                 15                      16    5     
                                                                                                                                                                  
  *Clinical response to primary chemotherapy*                           \<10^−3^                                                                                
   ⩾50%                                                                    104                                                63                      239   78    
   \<50%                                                                   60                                                 37                      67    22    
                                                                                                                                                                  
  *Hormonal receptors (DM*=*71*)                                          0.24                                                                                  
   ER+ and/or PR+                                                          99                                                 68                      192   74    
   ER−/PR−                                                                 46                                                 32                      68    26    

DM=data missing; ER=estradiol receptor; HR=hormonal receptor; PR=progesterone receptor.

53 preoperative radiotherapy and 115 exclusive radiotherapy.

###### 

Univariate and multivariate analyses of prognostic factors for locoregional recurrence-free survival

                                                         **Univariate analysis**   **Multivariate analysis**      
  ---------------------------- ---------- ------------- ------------------------- --------------------------- --- ----------------
  Age (continuous variable)                                       0.015                0.97 (0.96--1.00)                  
                                                                                                                          
  *Age (dummy variable)*^c^     \<10^−6^                        \<10^−3^                                          
   \>40                           597      79 (75--82)                                         1                         1
   ⩽40                            153      60 (51--70)                                  2.2 (1.6--3.1)             2.3 (1.6--3.2)
  *Menopause*                     0.5                                                                             
   No                             563      73 (69--78)                                         1                          
   Yes                            187      79 (73--86)                                  0.9 (0.6--1.3)                    
                                                                                                                          
  *Clinical tumour stage*^c^      0.35                                                                            
   cT2                            556      74 (69--78)                                         1                          
   cT3                            194      78 (72--86)                                  0.8 (0.6--1.2)                    
                                                                                                                          
  *Clinical nodal status*^c^      0.33                                                                            
   cN0                            465      76 (71--80)                                         1                          
   cN1                            285      74 (68--80)                                  1.2 (0.8--1.6)                    
                                                                                                                          
  *Histological type*             0.9                                                                             
   Ductal                         672      75 (71--79)                                         1                          
   Lobular                         78      73 (62--86)                                   1 (0.6--1.7)                     
                                                                                                                          
  *Hormonal receptors*^c^         0.05                            0.02                                            
   HR+                            466      75 (71--80)                                         1                         1
   HR−                            166      69 (62--78)                                  1.4 (1.0--2.0)             1.7 (1.2--2.5)
                                                                                                                          
  *Histological grade*            0.34                                                                            
   Grade 1                        114      82 (75--90)                                         1                          
   Grade 2                        362      73 (68--79)                                  1.3 (0.8--2.0)                    
   Grade 3                        217      73 (67--81)                                  1.4 (0.9--2.4)                    
                                                                                                                          
  *Mitotic index*                 0.48                                                                            
   Grade 1                        182      79 (72--87)                                         1                          
   Grade 2                        189      77 (70--84)                                  1.2 (0.7--1.9)                    
   Grade 3                        297      75 (69--81)                                  1.3 (0.8--2.0)                    
                                                                                                                          
  *Clinical response*             0.72                                                                            
   ⩾50%                           434      78 (74--83)                                         1                          
   \<50%                          309      76 (70--82)                                  1.1 (0.8--1.5)                    

HR=hormonal receptor; LRRFS=locoregional recurrence-free survival

Log-rank test.

Likelihood ratio test.

Factors entered in the multivariate analysis.

###### 

Univariate and multivariate analyses of prognostic factors for locoregional recurrence-free survival for patients treated by breast conservation

                                                         **Univariate analysis**   **Multivariate analysis^a^**      
  ---------------------------- ---------- ------------- ------------------------- ------------------------------ --- ----------------
  Age (continuous variable)                                      0.0009                 0.96 (0.94--0.98)                    
                                                                                                                             
  *Age (dummy variable)*^d^     \<10^−6^                        \<10^−5^                                             
   \>40                           382      77 (72--82)                                          1                           1
   ⩽40                             94      49 (38--63)                                    2.6 (1.8--3.7)              2.6 (1.7--3.7)
                                                                                                                             
  *Menopause*^d^                  0.1                                                                                
   No                             353      69 (63--74)                                          1                            
   Yes                            123      80 (73--88)                                    0.7 (0.4--1.1)                     
                                                                                                                             
  *Clinical tumour stage*^d^      0.81                                                                               
   cT2                            391      72 (67--77)                                          1                            
   cT3                             85      71 (60--83)                                    1.1 (0.7--1.7)                     
                                                                                                                             
  *Clinical nodal status*^d^      0.06                                                                               
   cN0                            315      73 (68--79)                                          1                            
   cN1                            161      68 (60--77)                                    1.4 (1.0--2.1)                     
                                                                                                                             
  *Histological type*^d^          0.12                                                                               
   Ductal                         434      72 (68--77)                                          1                            
   Lobular                         42      62 (47--82)                                    1.5 (0.9--2.6)                     
                                                                                                                             
  *Hormonal receptors*^d^         0.54                                                                               
   HR+                            291      72 (66--78)                                          1                            
   HR−                            114      68 (59--79)                                    1.1 (0.7--1.7)                     
                                                                                                                             
  *Histological grade*            0.97                                                                               
   Grade 1                         71      73 (63--85)                                          1                            
   Grade 2                        215      70 (63--77)                                    1.0 (0.6--1.6)                     
   Grade 3                        156      72 (64--81)                                    0.9 (0.5--1.6)                     
                                                                                                                             
  *Mitotic index*                 0.72                                                                               
   Grade 1                        110      71 (62--83)                                          1                            
   Grade 2                        125      72 (64--82)                                    1.1 (0.7--1.8)                     
   Grade 3                        195      70 (63--78)                                    1.2 (0.8--1.9)                     
                                                                                                                             
  *Clinical response*             0.29                                                                               
   ⩾50%                           343      74 (69--79)                                          1                            
   \<50%                          127      67 (58--77)                                    1.2 (0.8--1.8)                     
                                                                                                                             
  *Locoregional treatment*      \<10^−3^                                                                             
   Postop                         308      77 (71--83)                                                                       
   Preop/excl                     168      61 (53--70)                                    2.0 (1.4--2.8)                     

HR=hormonal receptor; LRRFS=locoregional recurrence-free survival

Multivariate analysis after stratification on local treatment.

Log-rank test.

Likelihood ratio test.

Factors entered in the multivariate analysis.

Preop/excl: locoregional treatment consisted in preoperative or exclusive radiotherapy.

###### 

Univariate and multivariate analyses of prognostic factors for overall survival

                                                           **Univariate analysis**   **Multivariate analysis**      
  ------------------------------ ---------- ------------- ------------------------- --------------------------- --- ----------------
  Age (continuous variable)                                          0.7                 1.0 (0.99--1.02)                   
                                                                                                                            
  *Age (dummy variable)*            0.11                                                                            
   \>40                             597      67 (63--72)                                         1                          
   ⩽40                              153      60 (52--69)                                  1.3 (0.9--1.7)                    
                                                                                                                            
  *Menopause*^a^                    0.22                                                                            
   No                               563      67 (63--72)                                         1                          
   Yes                              187      63 (55--71)                                  1.2 (0.9--1.6)                    
                                                                                                                            
  *Clinical tumour stage*^a^       0.005                                                                            
   cT2                              556      68 (64--73)                                         1                          
   cT3                              194      59 (51--67)                                  1.5 (1.1--1.9)                    
                                                                                                                            
  *Clinical nodal status*^a^      \<10^−7^                        \<10^−3^                                          
   cN0                              465      73 (69--78)                                         1                         1
   cN1                              285      54 (48--61)                                  2.0 (1.6--2.6)             2.1 (1.6--2.7)
                                                                                                                            
  *Histological type*               0.44                                                                            
   Ductal                           672      65 (61--69)                                         1                          
   Lobular                           78      72 (62--84)                                  0.8 (0.6--1.3)                    
                                                                                                                            
  *Hormonal receptors (HR)*^a^    \<10^−7^                        \<10^−3^                                          
   HR+                              466      70 (66--75)                                         1                         1
   HR−                              166      49 (42--58)                                  2.2 (1.7--2.8)             2.4 (1.8--3.2)
                                                                                                                            
  *Histological grade*^a,b^        0.0004                           0.02                                            
   Grade 1                          114      78 (69--87)                                         1                         1
   Grade 2                          362      66 (61--71)                                  1.8 (1.1--2.8)             1.8 (1.1--2.8)
   Grade 3                          217      58 (51--66)                                  2.5 (1.6--3.9)             1.9 (1.2--3.1)
                                                                                                                            
  *Mitotic index*^a^              \<10^−4^                                                                          
   Grade 1                          182      77 (70--85)                                         1                          
   Grade 2                          189      67 (60--74)                                  1.6 (1.1--2.4)                    
   Grade 3                          297      59 (53--65)                                  2.2 (1.5--3.2)                    
                                                                                                                            
  *Clinical response*^a^            0.15                            0.003                                           
   ⩾50%                             434      67 (63--73)                                         1                         1
   \<50%                            309      64 (58--70)                                  1.2 (0.9--1.6)             1.5 (1.2--2.0)

HR=hormonal receptor; LRRFS=locoregional recurrence-free survival

Factors entered in the multivariate analysis.

The mitotic index was not entered into the model as it was highly correlated with the histological grade.
